ACRS logo

Aclaris Therapeutics (ACRS) Operating Expenses

Annual Operating Expenses

$129.48 M
+$26.54 M+25.78%

December 31, 2023


Summary


Performance

ACRS Operating Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherACRSexpensesmetrics:

Quarterly Operating Expenses

$11.61 M
-$1.90 M-14.08%

September 30, 2024


Summary


Performance

ACRS Quarterly Operating Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherACRSexpensesmetrics:

Operating Expenses Formula

Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses

ACRS Operating Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+25.8%-62.1%
3 y3 years+159.7%-41.8%
5 y5 years+49.5%-49.6%

ACRS Operating Expenses Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+92.0%-66.7%at low
5 y5-yearat high+159.7%-66.7%+14.9%
alltimeall timeat high+2363.0%-66.7%+347.2%

Aclaris Therapeutics Operating Expenses History

DateAnnualQuarterly
Sep 2024
-
$11.61 M(-14.1%)
Jun 2024
-
$13.51 M(-19.0%)
Mar 2024
-
$16.69 M(-52.1%)
Dec 2023
$129.48 M(+25.8%)
$34.86 M(+13.6%)
Sep 2023
-
$30.67 M(-5.8%)
Jun 2023
-
$32.57 M(+3.8%)
Mar 2023
-
$31.38 M(+11.2%)
Dec 2022
$102.95 M(+52.7%)
$28.22 M(-4.2%)
Sep 2022
-
$29.47 M(+18.6%)
Jun 2022
-
$24.85 M(+21.8%)
Mar 2022
-
$20.41 M(-3.0%)
Dec 2021
$67.43 M(+35.2%)
$21.05 M(+5.5%)
Sep 2021
-
$19.95 M(+44.9%)
Jun 2021
-
$13.77 M(+8.7%)
Mar 2021
-
$12.66 M(-8.6%)
Dec 2020
$49.87 M(-45.8%)
$13.85 M(+37.2%)
Sep 2020
-
$10.10 M(-16.1%)
Jun 2020
-
$12.04 M(-13.3%)
Mar 2020
-
$13.88 M(-17.8%)
Dec 2019
$91.99 M
$16.89 M(-26.6%)
Sep 2019
-
$23.02 M(-7.9%)
DateAnnualQuarterly
Jun 2019
-
$24.99 M(-7.8%)
Mar 2019
-
$27.11 M(+4.1%)
Dec 2018
$86.60 M(+60.9%)
$26.05 M(+21.8%)
Sep 2018
-
$21.39 M(-35.1%)
Jun 2018
-
$32.97 M(+6.0%)
Mar 2018
-
$31.10 M(+307.9%)
Dec 2017
$53.84 M(+11.5%)
$7.63 M(-59.8%)
Sep 2017
-
$18.99 M(+32.8%)
Jun 2017
-
$14.29 M(+10.6%)
Mar 2017
-
$12.93 M(+14.2%)
Dec 2016
$48.27 M(+133.5%)
$11.33 M(+4.8%)
Sep 2016
-
$10.81 M(-16.8%)
Jun 2016
-
$12.99 M(-1.1%)
Mar 2016
-
$13.14 M(+173.6%)
Dec 2015
$20.67 M(+142.2%)
$4.80 M(-54.9%)
Sep 2015
-
$10.64 M(+309.9%)
Jun 2015
-
$2.60 M(-1.3%)
Mar 2015
-
$2.63 M(+1.0%)
Dec 2014
$8.53 M(+62.3%)
$2.60 M(-2.3%)
Sep 2014
-
$2.66 M
Dec 2013
$5.26 M
-

FAQ

  • What is Aclaris Therapeutics annual total operating expenses?
  • What is the all time high annual operating expenses for Aclaris Therapeutics?
  • What is Aclaris Therapeutics annual operating expenses year-on-year change?
  • What is Aclaris Therapeutics quarterly total operating expenses?
  • What is the all time high quarterly operating expenses for Aclaris Therapeutics?
  • What is Aclaris Therapeutics quarterly operating expenses year-on-year change?

What is Aclaris Therapeutics annual total operating expenses?

The current annual operating expenses of ACRS is $129.48 M

What is the all time high annual operating expenses for Aclaris Therapeutics?

Aclaris Therapeutics all-time high annual total operating expenses is $129.48 M

What is Aclaris Therapeutics annual operating expenses year-on-year change?

Over the past year, ACRS annual total operating expenses has changed by +$26.54 M (+25.78%)

What is Aclaris Therapeutics quarterly total operating expenses?

The current quarterly operating expenses of ACRS is $11.61 M

What is the all time high quarterly operating expenses for Aclaris Therapeutics?

Aclaris Therapeutics all-time high quarterly total operating expenses is $34.86 M

What is Aclaris Therapeutics quarterly operating expenses year-on-year change?

Over the past year, ACRS quarterly total operating expenses has changed by -$19.07 M (-62.15%)